Pharmacological therapy of spondyloarthritis

Bibliography

• Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777-83
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011;70:25-31
   PubMed Web of Science ®Google Scholar
• Olivieri I, D’Angelo S, Palazzi C, et al. Advances in the management of psoriatic arthritis. Nat Rev Rheumatol 2014;10:531-42
   PubMed Web of Science ®Google Scholar
• Mok CC, Tam LS, Leung MH, et al. Hong Kong Society of Rheumatology. Referral strategy for early recognition of axial spondyloarthritis: consensus recommendations from the Hong Kong Society of Rheumatology. Int J Rheum Dis 2013;16:500-8
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Sieper J. Referral strategies for early diagnosis of axial spondyloarthritis. Nat Rev Rheumatol 2012;8:262-8
   PubMed Web of Science ®Google Scholar
• Smolen JS, Sieper J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014;73:6-16
   PubMed Web of Science ®Google Scholar
• Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904
   PubMed Web of Science ®Google Scholar
• Wanders A, van der Heijde D, Landewé R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52:1756-65
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Rudwaleit M, Haibel H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012;71:1616-22
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Gajoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12
   PubMed Web of Science ®Google Scholar
• Lassus A. A comparative pilot study of azapropazone and indomethacin in the treatment of psoriatic arthritis and Reiter’s disease. Curr Med Res Opin 1976;4:65-9
   PubMedGoogle Scholar
• Leatham PA, Bird HA, Wright V, et al. The run-in period in trial design: a comparison of two non-steroidal antiinflammatory agents in psoriatic arthropathy. Agents Actions 1982;12:221-4
   PubMedGoogle Scholar
• Kivitz AJ, Espinoza LR, Sherrer YR, et al. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis. Semin Arthritis Rheum 2007;37:164-73
   PubMed Web of Science ®Google Scholar
• Sarzi-Puttini P, Santandrea S, Boccassini L, et al. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 2001;19(1 Suppl 22):S17-20
   PubMed Web of Science ®Google Scholar
• Borer JS, Simon LS. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. Arthritis Res Ther 2005;7(Suppl 4):S14-22
   PubMed Web of Science ®Google Scholar
• Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal antiinflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 2007;370:2138-51
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Jakobsen AK, Askling J, et al. Safety of etoricoxib, celecoxib and non-selective NSAIDs in Ankylosing Spondylitis and other Spondyloarthritis patients: A Swedish national population based cohort study. Arthritis Care Res (Hoboken) 2015; In press
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Kavanaugh A, Gladman DD, et al. for the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94
   PubMed Web of Science ®Google Scholar
• Fendler C, Baraliakos X, Braun J. Glucocorticoid treatment in spondyloarthritis. Clin Exp Rheumatol 2011;29(5 Suppl 68):S139-42
   PubMed Web of Science ®Google Scholar
• Haibel H, Fendler C, Listing J, et al. Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. Ann Rheum Dis 2014;73:243-6
   PubMed Web of Science ®Google Scholar
• Eder L, Chandran V, Ueng J, et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology (Oxford) 2010;49:1367-73
   PubMed Web of Science ®Google Scholar
• Chen J, Lis S, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2014;11:CD004800
   Google Scholar
• Ceponis A, Kavanaugh A. Use of methotrexate in patients with psoriatic arthritis. Clin Exp Rheumatol 2010;28(5 Suppl 61):S132-7
   PubMed Web of Science ®Google Scholar
• Abu-Shakra M, Gladman DD, Thorne JC, et al. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995;22:241-5
   PubMed Web of Science ®Google Scholar
• Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. J Rheumatol 2008;35:469-71
   PubMed Web of Science ®Google Scholar
• Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 2012;51:1368-77
   PubMed Web of Science ®Google Scholar
• Mease PJ. Spondyloarthritis: Is methotrexate effective in psoriatic arthritis? Nat Rev Rheumatol 2012;8:251-2
   PubMed Web of Science ®Google Scholar
• Behrens F, Finkenwirth C, Pavelka K, et al. Leflunomide in psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res (Hoboken) 2013;65:464-70
   PubMed Web of Science ®Google Scholar
• Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939-50
   PubMed Web of Science ®Google Scholar
• Sakellariou GT, Sayegh FE, Anastasilakis AD, et al. Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate. Rheumatol Int 2013;33:2917-20
   PubMed Web of Science ®Google Scholar
• Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999;42:2325-9
   PubMed Web of Science ®Google Scholar
• Gupta A. K, Grober JS, Hamilton TA, et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 1995;22:894-8
   PubMed Web of Science ®Google Scholar
• Rahman P, Gladman DD, Cook RJ, et al. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol 1998;25:1957-61
   PubMed Web of Science ®Google Scholar
• Salvarani C, Macchioni P, Olivieri I, et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001;28:2274-82
   PubMed Web of Science ®Google Scholar
• Sarzi-Puttini P, Cazzola M, Panni B, et al. Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis. Rheumatol Int 2002;21:234-8
   PubMed Web of Science ®Google Scholar
• Fraser AD, van Kuijk AW, Westhovens R, et al. A randomized double blind,placebo controlled, multicenter trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005;64:859-64
   PubMed Web of Science ®Google Scholar
• Kelly JB3rd, Foley P, Strober BE. Current and future oral systemic therapies for psoriasis. Dermatol Clin 2015;33:91-109
   PubMed Web of Science ®Google Scholar
• Strober BE. Methotrexate and cyclosporine in psoriasis revisited. Semin Cutan Med Surg 2014;33(2 Suppl 2):S27-30
   PubMedGoogle Scholar
• Schmitt J, Rosumeck S, Thomaschewski G, et al. Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2014;170:274-303
   PubMed Web of Science ®Google Scholar
• D’Angelo S, Palazzi C, Olivieri I. Psoriatic arthritis: treatment strategies using biologic agents. Reumatismo 2012;64:113-21
   PubMedGoogle Scholar
• Mease P J, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014;73:48-55
   PubMedGoogle Scholar
• Goulabchand R, Mouterde G, Barnetche T, et al. Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and metaanalysis of randomised controlled trials. Ann Rheum Dis 2014;73:414-19
   PubMed Web of Science ®Google Scholar
• Atteno M, Peluso R, Costa L, et al. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol 2010;29:399-403
   PubMed Web of Science ®Google Scholar
• Fénix-Caballero S, Alegre-del Rey EJ, Castaño-Lara R, et al. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. J Clin Pharm Ther 2013;38:286-93
   PubMed Web of Science ®Google Scholar
• Thorlund K, Druyts E, Aviña-Zubieta JA, et al. Anti-tumor necrosis factor (TNF)drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis. Biologics 2012;6:417-27
   PubMedGoogle Scholar
• Baraliakos X, van den Berg R, Braun J, et al. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology (Oxford) 2012;51:1378-87
   PubMed Web of Science ®Google Scholar
• Callhoff J, Sieper J, Weiß A, et al. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis 2014; In press
   Google Scholar
• Lubrano E, Perrotta FM, Marchesoni A, et al. Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian Multicenter Study. J Rheumatol 2015;42:258-63
   PubMed Web of Science ®Google Scholar
• Ciurea A, Weber U, Stekhoven D. Treatment with tumor necrosis factor inhibitors in axial spondyloarthritis: comparison between private rheumatology practices and academic centers in a large observational cohort. J Rheumatol 2015;42:101-5
   PubMed Web of Science ®Google Scholar
• Chen JS, Makovey J, Lassere M, et al. Comparative effectiveness of anti-tumour necrosis factor (TNF) drugs on health-related quality of life among patients with inflammatory arthritis. Arthritis Care Res (Hoboken) 2014;66:464-72
   PubMed Web of Science ®Google Scholar
• Shu T, Chen GH, Rong L, et al. Indirect comparison of anti-TNF-alpha agents for active ankylosing spondylitis: mixed treatment comparison of randomized controlled trials. Clin Exp Rheumatol 2013;31:717-22
   PubMed Web of Science ®Google Scholar
• Migliore A, Broccoli S, Bizzi E, et al. Indirect comparison of the effects of anti-TNF biological agents patients with ankylosing spondylitis means of a mixed treatment comparison performed on efficacy data from published randomised, controlled trials. J Med Econ 2012;15:473-80
   PubMedGoogle Scholar
• Braun J, Pavelka K, Ramos-Remus C, et al. Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement. J Rheumatol 2012;39:836-40
   PubMed Web of Science ®Google Scholar
• Zisman D, Haddad A, Hashoul S, et al. Hospitalizations of patients treated with anti-tumor necrosis factor-alpha agents - a retrospective cohort analysis. J Rheumatol 2013;40:16-22
   PubMed Web of Science ®Google Scholar
• Glintborg B, Hansen M, Østergaard M, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti–tumor necrosis factor therapy. Arthritis Rheum 2011;63:382-90
   PubMed Web of Science ®Google Scholar
• Iervolino S, Di Minno MN, Peluso R, et al. Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-a blockers. J Rheumatol 2012;39:568-73
   PubMedGoogle Scholar
• Bruner V, Atteno M, Spanò A, et al. Biological therapies for spondyloarthritis. Ther Adv Muskuloskel Dis 2014;6:92-101
   PubMedGoogle Scholar
• Mirjam K, De Vries M, Van Eijk I, et al. Levels of ESR, CRP, and SAA and anti-TNF therapy in AS patients. Arthritis Rheum 2009;61:1484-90
   PubMedGoogle Scholar
• Arends S, Brouwer E, van der Veer E, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: prospective longitudinal observational cohort. Arthritis Res Ther 2011;13:R94
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Salonen D, Weissman BN, et al. Canadian (M03-606) study group; ATLAS study group. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009;11:R127
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Landewé R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58(10):3063-70
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-31
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Haibel H, Listing J, et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2014;73:710-15
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Hermann KG, et al. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis 2014;73:1107-13
   PubMed Web of Science ®Google Scholar
• Haroon N, Inman RD, Laerch TJ, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013;65:2645-54
   PubMed Web of Science ®Google Scholar
• van Tubergen A, Ramiro S, van der Heijde D, et al. Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. Ann Rheum Dis 2012;71:518-23
   PubMed Web of Science ®Google Scholar
• Ramiro S, van der Heijde D, van Tubergen A, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis 2014;73:1455-61
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Listing J, Fritz C, et al. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome. Rheumatology (Oxford) 2011;50:1690-9
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Haibel H, Fritz C, et al. Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther 2013;15:R67
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Heldmann F, et al. Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis. Expert Opin Invest Drugs 2014;23:647-59
   PubMed Web of Science ®Google Scholar
• Biggioggero M, Favalli EG. Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides. Drug Dev Res 2014;75(Suppl 1):S38-41
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Nannini C, et al. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology (Oxford) 2008;47:872-6
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Cassarà E, et al. Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study. Biologics 2012;6:201-6
   PubMedGoogle Scholar
• Haibel H, Heldmann F, Listing J, et al. Long-term efficacy of adalimumab after drug withdrawal and retreatment of flare patients in active non-radiographic, axial spondyloarthritis. Arthritis Rheum 2013;65:2211-13
   PubMed Web of Science ®Google Scholar
• Song IH, Althoff CE, Haibel H, et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis 2012;71:1212-15
   PubMed Web of Science ®Google Scholar
• Braun J, Sieper J. Remission and possible discontinuation of biological therapy in axial spondyloarthritis. Clin Exp Rheumatol 2013;31(4 Suppl 78):S33-6
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Kiltz U, Heldmann F, et al. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in established disease. Clin Exp Rheumatol 2013;31(4 Suppl 78):S43-6
   PubMed Web of Science ®Google Scholar
• Song IH, Haibel H, Poddubnyy D, et al. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease. Clin Exp Rheumatol 2013;31(4 Suppl 78):S37-42
   PubMed Web of Science ®Google Scholar
• Olivieri I, D’Angelo S, Padula A, et al. Can we reduce the dosage of biologics in spondyloarthritis? Autoimmun Rev 2013;12:691-3
   PubMed Web of Science ®Google Scholar
• Fabbroni M, Cantarini L, Caso F, et al. Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. Mediators Inflamm 2014;2014:862969
   PubMed Web of Science ®Google Scholar
• Spadaro A, Lubrano E, Marchesoni A, et al. Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study. Rheumatology (Oxford) 2013;52:1914-19
   PubMed Web of Science ®Google Scholar
• Fagerli KM, Lie E, van der Heijde D, et al. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis 2013;72(11):1840-4
   PubMed Web of Science ®Google Scholar
• Glintborg B, Østergaard M, Krogh NS, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 2013;72:1149-55
   PubMed Web of Science ®Google Scholar
• Paccou J, Solau-Gervais E, Houvenagel E, et al. Efficacy in current practice of switching between anti-tumour necrosis factor- α agents in spondyloarthropathies. Rheumatology (Oxford) 2011;50:714-20
   PubMed Web of Science ®Google Scholar
• Plasencia C, Pascual-Salcedo D, García-Carazo S, et al. The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients. Arthritis Res Ther 2013;15:R79
   PubMed Web of Science ®Google Scholar
• Behrens F, Cañete JD, Olivieri I, et al. Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. Rheumatology (Oxford) 2015;54:915-26
   PubMed Web of Science ®Google Scholar
• Fagerli KM, Lie E, van der Heijde D, et al. The role of methotrexate co-medication inTNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2014;73:132-7
   PubMed Web of Science ®Google Scholar
• Durnez A, Paternotte S, Fechtenbaum J, et al. Increase in bone density in patients with spondyloarthritis during anti-tumor necrosis factor therapy: 6-year followup study. J Rheumatol 2013;40:1712-18
   PubMed Web of Science ®Google Scholar
• Haroon NN, Sriganthan J, Al Ghanim N, et al. Effect of TNF-alpha inhibitor treatment on bone mineral density in patients with ankylosing spondylitis: a systematic review and meta-analysis. Semin Arthritis Rheum 2014;44:155-6
   PubMed Web of Science ®Google Scholar
• Viapiana O, Gatti D, Idolazzi L, et al. Bisphosphonates vs infliximab in ankylosing spondylitis treatment. Rheumatology (Oxford) 2014;53:90-4
   PubMed Web of Science ®Google Scholar
• El Maghraoui A. Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med 2011;22:554-60
   PubMed Web of Science ®Google Scholar
• Brezinski EA, Armstrong AW. Strategies to maximize treatment success in moderate to severe psoriasis: establishing treatment goals and tailoring of biologic therapies. Semin Cutan Med Surg 2014;33:91-7
   PubMed Web of Science ®Google Scholar
• Lynch M, Kirby B, Warren RB. Treating moderate to severe psoriasis - best use of biologics. Expert Rev Clin Immunol 2014;10:269-79
   PubMed Web of Science ®Google Scholar
• Kim IH, West CE, Kwatra SG, et al. Comparative efficacy of biologics in psoriasis: a review. Am J Clin Dermatol 2012;13:365-74
   PubMed Web of Science ®Google Scholar
• Cordero-Coma M, Yilmaz T, Onal S. Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis. Ocul Immunol Inflamm 2013;21:19-27
   PubMed Web of Science ®Google Scholar
• Wendling D. Uveitis in seronegative arthritis. Curr Rheumatol Rep 2012;14:402-8
   PubMed Web of Science ®Google Scholar
• Dubé PE, Punit S, Polk DB. Redeeming an old foe: protective as well as pathophysiological roles for tumor necrosis factor in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2015;308:G161-70
   PubMed Web of Science ®Google Scholar
• Mandel MD, Miheller P, Müllner K, et al. Have biologics changed the natural history of Crohn’s disease? Dig Dis 2014;32:351-9
   PubMed Web of Science ®Google Scholar
• Antunes O, Filippi J, Hébuterne X, et al. Treatment algorithms in Crohn’s - up, down or something else? Best Pract Res Clin Gastroenterol 2014;28:473-83
   PubMed Web of Science ®Google Scholar
• Stidham RW, Lee TC, Higgins PD, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther 2014;39:1349-62
   PubMed Web of Science ®Google Scholar
• Fausel R, Afzali A. Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists. Ther Clin Risk Manag 2015;11:63-73
   PubMed Web of Science ®Google Scholar
• Olivieri I, Cantini F, Castiglione F, et al. Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. Autoimmun Rev 2014;13:822-30
   PubMed Web of Science ®Google Scholar
• McInnes IB, Rahman P, Kavanaugh A, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013;382:780-9
   PubMed Web of Science ®Google Scholar
• Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014;73:990-9
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 2014;73:1000-6
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Hermann KG, Callhoff J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 2014;73:817-23
   PubMed Web of Science ®Google Scholar
• Stamell E F, Kutner A, Viola K, Cohen SR. Ustekinumab associated with flares of psoriatic arthritis. JAMA Dermatol 2013;149:1410-13
   PubMed Web of Science ®Google Scholar
• de Souza A, Ali-Shaw T, Reddy SM, et al. Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases. Br J Dermatol 2013;168(1):210-12
   PubMed Web of Science ®Google Scholar
• Lekpa FK, Farrenq V, Canouï-Poitrine F, et al. Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition. Joint Bone Spine 2012;79:47-50
   PubMed Web of Science ®Google Scholar
• Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011;70:1108-10
   PubMed Web of Science ®Google Scholar
• Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011;63:939-48
   PubMed Web of Science ®Google Scholar
• Song IH, Heldmann F, Rudwaleit M, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010;62:1290-7
   PubMed Web of Science ®Google Scholar
• Wendling D, Dougados M, Berenbaum F, et al. French Society of Rheumatology and the Club Rhumatismes et Inflammation. Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology. J Rheumatol 2012;39:2327-31
   PubMed Web of Science ®Google Scholar
• Sieper J, Porter-Brown B, Thompson L, et al. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 2014;73:95-100
   PubMed Web of Science ®Google Scholar
• Sieper J, Braun J, Kay J, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis 2014;10.1136/annrheumdis-2013-204963. [Epub ahead of print]
   Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014;73:1020-6
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis. J Rheumatol 2015;42(3):479-88
   PubMed Web of Science ®Google Scholar
• Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012;64:3156-67
   PubMed Web of Science ®Google Scholar
• Pathan E, Abraham S, Van Rossen E, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis 2013;72:1475-80
   PubMed Web of Science ®Google Scholar
• Patel DD, Lee DM, Kolbinger F, et al. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis 2013;72(Suppl 2):ii116-23
   PubMed Web of Science ®Google Scholar
• Gisondi P, Dalle Vedove C, Girolomoni G. Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy. Dermatol Ther (Heidelb) 2014;4:1-9
   PubMedGoogle Scholar
• Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013;382(9906):1705-13; Erratum in: Lancet 2014;383(9928):1548
   PubMed Web of Science ®Google Scholar
• McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014;73:349-56
   PubMed Web of Science ®Google Scholar
• Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014;370:2295-306
   PubMed Web of Science ®Google Scholar
• Tan AL, Marzo-Ortega H, O’Connor P, et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 2004;63:1041-5
   PubMed Web of Science ®Google Scholar
• Haibel H, Rudwaleit M, Listing J, et al. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005;64:296-8
   PubMed Web of Science ®Google Scholar
• Jung N, Hellmann M, Hoheisel R, et al. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin Rheumatol 2010;29:1169-73
   PubMed Web of Science ®Google Scholar
• Palazzi C, D’Angelo S, Lubrano E, et al. New insights in occult psoriatic arthritis. J Rheumatol Suppl 2012;89:22-3
   PubMedGoogle Scholar
• Palazzi C, Lubrano E, D’Angelo S, et al. Beyond early diagnosis: occult psoriatic arthritis. J Rheumatol 2010;37:1556-8
   PubMed Web of Science ®Google Scholar
• Palazzi C, Olivieri I, D’Amico E, et al. Management of reactive arthritis. Expert Opin Pharmacother 2004;5:61-70
   PubMed Web of Science ®Google Scholar
• Carter JD, Espinoza LR, Inman RD, et al. Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. Arthritis Rheum 2010;62:1298-307
   PubMed Web of Science ®Google Scholar
• Barber CE, Kim J, Inman RD, et al. Antibiotics for treatment of reactive arthritis: a systematic review and metaanalysis. J Rheumatol 2013;40:916-28
   PubMed Web of Science ®Google Scholar